Clinical trials are necessary to evaluate the therapeutic value of TNF blockade strategy in melanoma patients and define the eligibility criteria such as (i) TNF expression in melanoma biopsies, (ii) pre-existing CD8+ T cell infiltration, (iii) MHCI expression by melanoma cells. This evidence concerns the gene TNF and melanoma.